-
2 months ago | 
onlinelibrary.wiley.com | Alyson Haslam |Timothée Olivier |Vinay Prasad
CONFLICT OF INTEREST STATEMENT V. P. receives research funding from Arnold Ventures through a grant made to UCSF and royalties for books and writing from Johns Hopkins Press, MedPage, and the Free Press.
-
Jun 20, 2024 | 
open.substack.com | Timothée Olivier
Together with Alyson Haslam and Vinay Prasad, we have a new paper out in JAMA oncology ! We looked at all adjuvant & neoadjuvant drugs approved by the US Food and Drug Administration from 2018 to 2023 (May). In cases of localized cancer treated with surgery, treatments administered before (neoadjuvant) or after (adjuvant) the operation aim to reduce the risk of recurrence, increase the chances of cure, and allow for less invasive surgery.
-
Jun 20, 2024 | 
jamanetwork.com | Timothée Olivier |Alyson Haslam |Vinay Prasad
Key PointsQuestion How often is postrecurrence treatment reported in adjuvant and neoadjuvant oncology randomized clinical trials, and what is the access to optimal postrecurrence treatment? Findings In this systematic review of 14 US Food and Drug Administration registration trials of systemic therapy in the neoadjuvant or adjuvant setting from 2018 to 2023, postrecurrence treatment was not reported in 43% of trials. Overall, 14% of trials had data assessed as appropriate.
-
May 17, 2024 | 
drugdevletter.com | Timothée Olivier
FRIDAY’S GEM, EDITORS’S PICKIn this section, every week, we present a paper that cought our attention, it can be recent, seminal, historical, a point of view, a commentary, a clinical trial, any publication that we feel is important!The E1193 trial is an example of a practice-informing trial, which serves as a refreshing reminder of how to interpret or incorporate novel findings.
-
May 15, 2024 | 
drugdevletter.com | Timothée Olivier
In this ASCO 2024 series, we provide background in expectation of the results to be presented during the upcoming ASCO 2024 meeting, which will take place between 31th May and 4th June. The annual congress of the American Society of Clinical Oncology is a key event in oncology. Each year, it attracts more than 30,000 attendees in Chicago. EGFR is a proto-oncogene.
-
May 10, 2024 | 
drugdevletter.com | Timothée Olivier
In this section, every week, we present a paper that cought our attention, it can be recent, seminal, historical, a point of view, a commentary, a clinical trial, any publication that we feel is important!Let’s start this new column of the “Drug Develpment Letter” with this insightful comment by our friends and colleagues Ghulam Mohyuddin and Aaron Goodman.
-
May 8, 2024 | 
drugdevletter.com | Timothée Olivier
In this ASCO 2024 series, we provide background in expectation of the results to be presented during the upcoming ASCO 2024 meeting, which will take place between 31th May and 4th June. The annual congress of the American Society of Clinical Oncology is a key event in oncology. Each year, it attracts more than 30,000 attendees in Chicago. Patients with resected melanoma are often proposed adjuvant immunotherapy, i.e. AFTER surgical removal, depending on the disease stage, based on DFS or EFS gains.
-
Nov 28, 2023 | 00474-6/abstract&sz=64)
thelancet.com | Timothée Olivier |Alfredo Addeo
We thank Timothée Olivier and Alfredo Addeo for their interest in our Article.1 For the survival analysis, there were 92 deaths. Figure 2 in our Article1 displayed 91 deaths occurring over 54 months of follow-up; however, an additional death occurred between 54 months and 60 months. A Kaplan-Meier curve showing survival over 60 months (with 92 deaths) is provided in the appendix (p 2).
-
Oct 31, 2023 | 
developdrugs.substack.com | Timothée Olivier
In JAMA Network Open 26 October 2023, (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811111) we show for the first time in the history of drug development that an entire drug pipeline is unequally accessible according to patient's race or ethnicity. When it comes to trial eligibility for HLA-based drugs, White patients are favored over Black individuals and other ethnicities. How could this happen? What would be the solutions to overcome such inequity? A primer is needed.
-
Oct 26, 2023 | 
jamanetwork.com | Timothée Olivier |Alyson Haslam |Jordan E. Tuia
Key PointsQuestion Is availability of therapeutics for patients with specific human leukocyte antigen (HLA) subtypes associated with inequalities by race and ethnicity?
